DEF: Aimei Health to Merge with United Hydrogen

Aimei Health Technology Co., Ltd. (Aimei Health) has announced a definitive business combination agreement to merge with United Hydrogen Group Inc., forming United Hydrogen Global Inc. (Pubco), a hydrogen solutions provider, in a $1.5 billion all-stock transaction.

Summary

• Aimei Health Technology Co., Ltd. (Purchaser), a Cayman Islands-incorporated SPAC, is merging with United Hydrogen Group Inc. (Company), a Cayman Islands-incorporated hydrogen solutions provider, to form United Hydrogen Global Inc. (Pubco).
• The business combination is structured as a "double dummy" merger, where First Merger Sub merges into United Hydrogen, and Second Merger Sub merges into Aimei Health, with both surviving as wholly-owned subsidiaries of Pubco.
• The aggregate merger consideration for United Hydrogen shareholders is $1.5 billion, to be paid entirely in newly issued Class A and Class B Ordinary Shares of Pubco, with each share valued at $10.00.
• Pubco will have a dual-class voting structure: Class A Ordinary Shares get one vote per share, and Class B Ordinary Shares get ten votes per share.
• Ms. Xia Ma, United Hydrogen's founder and director, will beneficially own all 90,808,887.50 Pubco Class B Ordinary Shares, representing approximately 93.15% of the aggregate voting power (assuming no redemptions).
• Aimei Health's public shareholders will experience immediate and material dilution upon closing. Assuming no redemptions, they will own approximately 2.54% of Pubco's outstanding shares. With maximum contractual redemptions, this drops to 0.18%.
• The transaction requires approval from both Aimei Health and United Hydrogen shareholders. An Extraordinary General Meeting for Aimei Health shareholders is scheduled for November 6, 2025.
• Pubco will apply for listing its Class A Ordinary Shares on the Nasdaq Capital Market under the symbol UHL.
• United Hydrogen's revenue for the fiscal year ended December 31, 2024, was approximately $52.6 million, with a net income of $0.6 million. This is an increase from $13.1 million revenue and $0.1 million net income in 2023.
• The Aimei Health board of directors unanimously approved the Business Combination, supported by a fairness opinion from CHFT Advisory and Appraisal Ltd., which valued United Hydrogen between $1.209 billion and $1.742 billion.
• United Hydrogen is required to complete filing procedures with the China Securities Regulatory Commission (CSRC) for its indirect overseas offering and listing, and the CSRC review process is ongoing.

Sentiment

Score: 4

Explanation: The proposed business combination presents a compelling opportunity to invest in a rapidly growing hydrogen energy solutions provider in China, a sector with strong government support and significant market potential. United Hydrogen's impressive revenue and net income growth in 2024, coupled with its comprehensive business model and strategic expansion plans, are positive indicators. However, the transaction carries substantial risks that warrant caution. The severe dilution for Aimei Health's public shareholders, the concentrated voting power in Ms. Xia Ma through the dual-class structure, and the ongoing regulatory uncertainties in China (including the critical CSRC approval and potential HFCA Act delisting risks) introduce considerable downside. Furthermore, United Hydrogen's historical negative operating cash flows and reliance on shareholder capital injections highlight liquidity concerns. While the long-term growth prospects of the hydrogen industry are attractive, the immediate risks and the potential for adverse regulatory outcomes suggest a 'hold' recommendation. Investors should closely monitor the CSRC approval process, Pubco's post-merger financial performance, and any further regulatory developments in China before making a definitive investment decision.

Positives

• United Hydrogen's revenue increased significantly by 301% from $13.1 million in 2023 to $52.6 million in 2024.
• Net income for United Hydrogen grew from $0.1 million in 2023 to $0.6 million in 2024, a 316% increase.
• United Hydrogen operates in the rapidly developing hydrogen energy industry in China, supported by favorable government policies and initiatives.
• The company offers comprehensive hydrogen solutions, covering production, refueling, and commercial applications, positioning it as an integrator in the hydrogen value chain.
• United Hydrogen has an experienced management team with extensive industry knowledge and a proven track record.
• The company plans to expand its business by participating in the hydrogen supply chain, establishing a "Giga Plant" in Jiaxing, developing new generation fuel cell forklifts, and exploring green hydrogen opportunities.
• The transaction provides United Hydrogen with increased access to capital markets and enhanced market visibility through a Nasdaq listing.
• The Aimei Health board received a fairness opinion from an independent valuation consultancy, CHFT Advisory and Appraisal Ltd., supporting the fairness of the consideration.
• United Hydrogen's management projects significant revenue growth, with a compound annual growth rate (CAGR) of approximately 77% from 2025 to 2028.

Negatives

• Aimei Health's public shareholders will experience immediate and material dilution, with ownership potentially dropping to 0.18% in a maximum redemption scenario.
• The dual-class voting structure concentrates 93.15% of voting power (assuming no redemptions) in Ms. Xia Ma, United Hydrogen's founder, potentially misaligning her interests with other shareholders and creating an anti-takeover effect.
• United Hydrogen had negative net operating cash flows in 2023 and 2024, exposing it to liquidity risks.
• The company faces significant customer and supplier concentration risks, with a few key entities accounting for substantial portions of receivables, payables, and revenues.
• The business is capital-intensive, and future financing sources are uncertain, with reliance on shareholder capital injections.
• United Hydrogen's operations in China are subject to complex and rapidly evolving PRC laws and regulations, including potential government intervention, cybersecurity oversight, and data security laws, which could materially impact operations and share value.
• The CSRC review process for the overseas listing is ongoing, and failure to obtain approval could terminate the Business Combination.
• The Holding Foreign Companies Accountable Act (HFCA Act) poses a delisting risk if the PCAOB is unable to inspect Pubco's auditors for two consecutive years.
• Aimei Health's independent auditor's report contains an explanatory paragraph expressing substantial doubt about Aimei Health's ability to continue as a going concern.
• The Sponsor of Aimei Health acquired founder shares at a significantly lower price ($0.014 per share) compared to public shareholders ($10.00 per share), leading to material dilution for non-redeeming public shareholders.
• The fairness opinion obtained by Aimei Health's board does not reflect changes or events after its date (June 19, 2024).
• The Business Combination is subject to numerous closing conditions, and failure to satisfy or waive them could lead to termination.
• The lack of an independent third-party underwriter in the de-SPAC transaction means investors do not benefit from the same level of due diligence or price stabilization as in a traditional IPO.
• Pubco will incur higher costs as a public company and may not pay cash dividends in the foreseeable future.
• Certain leasehold interests of United Hydrogen's PRC subsidiaries may be defective, and some lease agreements have not been registered with relevant authorities.
• The company has not made adequate social insurance and housing fund contributions for all employees in its PRC subsidiaries, potentially leading to penalties.

Risks

• If unable to manage growth or execute strategies effectively, business and prospects may be materially and adversely affected.
• Changes in Chinese government policies and regulatory frameworks supporting the hydrogen energy industry may significantly impact operations.
• Demand for hydrogen services and products may not develop as expected, leading to revenue shortfalls.
• The rapidly evolving and competitive nature of the hydrogen industry makes future prospects difficult to evaluate, with risks of technological lag or failure to launch competitive products.
• Significant product defects, failures, or negative publicity in the hydrogen fuel cell vehicle industry could damage reputation and adversely affect business.
• Negative net operating cash flows in the past expose the company to liquidity risks and constrain operational flexibility.
• Customer concentration risk: loss of significant customers or their failure to cooperate could materially and adversely affect revenue and profit.
• Challenges in retaining long-term relationships with and seeking legal remedies against significant customers who are government agencies or state-owned enterprises.
• Reliance on third-party suppliers exposes the company to risks of quality control issues, supply chain interruptions, increased costs, and difficulty in securing alternatives.
• Failure to maintain an effective quality and safety control system could significantly impact business, reputation, and financial condition, especially given the hazardous nature of hydrogen.
• Exposure to product safety issues, product liability, or other claims related to hydrogen production, refueling, and fuel cell systems.
• Capital-intensive business with uncertain future financing sources, potentially leading to reliance on shareholder injections.
• Inability to obtain or renew certain approvals, licenses, permits, or certifications required for business operations.
• Failure to obtain, or reduction/cancellation of, government subsidies may adversely affect business.
• Global inflationary pressures, including fuel price inflation, could negatively impact results of operations and cash flows.
• Intense competition in the hydrogen industry from larger, more resourced competitors.
• Credit risks from customers, particularly due to long payment days and unsecured receivables.
• Risks associated with maintaining large balances of accounts receivable and accounts payable.
• Risks in managing inventory, including damage, impairment, or obsolescence.
• Failure to attract or retain an experienced management team and qualified personnel.
• High dependence on Ms. Xia Ma, Pubco's Chairperson, Director, CEO, and ultimate controlling shareholder.
• Status as an emerging growth company may make Pubco Class A Ordinary Shares less attractive to investors.
• Failure to protect intellectual property rights and proprietary information could lead to loss of competitive edge.
• Computer system failures, cyber-attacks, or cybersecurity deficiencies could disrupt operations.
• Limited insurance coverage could expose the company to significant costs and business disruption.
• Changes in China's economic, political, or social conditions or government policies could have a material adverse effect on operations and Pubco's securities value.
• The Chinese government may promulgate laws, regulations, or policies that increase scrutiny or revise the regulatory regime, potentially leading to material changes in operations or worthlessness of securities.
• The Chinese government's broad oversight and discretion may enable intervention in operations at any time.
• Rapid, unpredictable changes in PRC laws, regulations, and policies can limit legal protections.
• Cash or assets held in the PRC may face restrictions on transfer outside the country due to government regulations, foreign exchange controls, statutory reserves, and taxes.
• Chinese regulatory authorities could disallow Pubco's holding company structure, resulting in material changes to operations or value of securities.
• The filing with the CSRC is required for the Business Combination, and there is no prediction on obtaining approval or completing the filing.
• The Opinions, Trial Measures, and revised Provisions recently issued by PRC authorities may subject the company to additional compliance requirements.
• Greater oversight by the CAC over data security, particularly for companies seeking foreign listing, could adversely impact business.
• Failure to comply with PRC Data Security and Personal Information Protection Laws could result in material adverse effects.
• Future changes in PRC Outbound Direct Investment Regulations could impact the ability to make further outbound investments.
• Uncertainties in the interpretation and enforcement of the newly enacted Foreign Investment Law.
• Difficulties in effecting service of legal process, enforcing foreign judgments, or bringing actions in China against the company or its management based on foreign laws.
• The M&A Rules and other PRC regulations may make it more difficult to pursue growth through acquisitions.
• Changes in currency conversion rates (RMB to USD) may affect the value of investments.
• Joint statements by the SEC and PCAOB, Nasdaq rule changes, and the HFCA Act call for more stringent criteria for emerging market companies, adding uncertainties to Nasdaq listing or future offerings.
• Aimei Health shareholders may experience substantial dilution and reduced influence over management.
• Sale or availability of substantial amounts of Pubco Class A Ordinary Shares could adversely affect market price.
• The fairness opinion does not reflect changes after its date (June 19, 2024).
• Consummation is subject to conditions that may not be satisfied or waived, leading to termination.
• Initial Shareholders (Sponsor, directors, officers) have conflicts of interest due to their investment structure and potential for substantial profit even if public shareholders lose money.
• If the Business Combination is not completed by December 6, 2025 (extended deadline), Aimei Health will liquidate, and public shareholders may receive less than $10.10 per share, and rights will be worthless.
• Becoming a public company through a business combination (de-SPAC) presents risks to unaffiliated investors compared to an underwritten offering (e.g., less independent due diligence, no book-building process).
• Pubco's share price may be volatile and could decline substantially.
• The grant and future exercise of registration rights may adversely affect the market price of Pubco's securities.
• If the Business Combination's benefits do not meet expectations, Pubco's share price may decline.
• Litigation relating to the Business Combination could result in injunctions or substantial costs.
• Pubco's success depends on the efforts of key personnel, and loss of such personnel could negatively impact operations.
• Aimei Health's due diligence may not have identified all material risks.
• Activities by existing shareholders to increase approval likelihood could depress Aimei Health's securities.
• Proceeds in the Trust Account could be reduced by third-party claims if Aimei Health liquidates.
• Aimei Health may not have sufficient funds to satisfy indemnification claims of its directors and executive officers.
• Aimei Health's directors may decide not to enforce the Sponsor's indemnification obligations.
• Bankruptcy filing could prioritize creditors over public shareholders.
• Public shareholders may wait up to 24 months for redemption from the Trust Account if the business combination is not consummated.
• Holders of rights will not have redemption rights and their rights will expire worthless if the business combination fails.
• Changes in laws, regulations, or rules may adversely affect the Business Combination and Pubco's securities.
• Difficulties in protecting interests due to Cayman Islands incorporation and limited U.S. federal court access.
• Economic substance legislation of the Cayman Islands may adversely impact Aimei Health or its operations.
• Projections are inherently subjective and may not be realized; actual results could differ materially.
• United Hydrogen management made numerous material estimates in developing projections, which may prove incorrect.
• A decline in financial forecast or failure to meet forecasted results may adversely affect future financial condition.
• Pubco will incur higher costs as a public company.
• Pubco may or may not pay cash dividends in the foreseeable future.
• Reduced SEC reporting requirements as an emerging growth company may make Pubco Class A Ordinary Shares less attractive.
• As a foreign private issuer, Pubco is permitted to file less or different information and follow home-country corporate governance practices, potentially offering less protection to shareholders.
• Pubco will be a controlled company, allowing Ms. Xia Ma to elect not to comply with certain corporate governance standards.
• Pubco's dual-class capital structure may render Class A Ordinary Shares ineligible for certain stock market indices.
• Economic substance legislation of the Cayman Islands may adversely impact Pubco or its operations.

Future Outlook

Pubco intends to retain future earnings to finance business expansion and does not anticipate paying cash dividends in the foreseeable future. United Hydrogen plans to expand its business across the entire hydrogen ecosystem, including production, storage, transportation, refueling, equipment supply, and commercial applications. Key strategies involve participating in the hydrogen supply chain, establishing a 'Giga Plant' in Jiaxing, developing new generation hydrogen fuel cell forklifts, strengthening its presence in key Chinese regions, and expanding into international markets like Southeast Asia and the Middle East. The company also aims to explore green hydrogen technology and related commercial applications. Management projects a compound annual revenue growth rate (CAGR) of approximately 77% from 2025 to 2028, with anticipated revenues of $178.9 million in 2025, $377.5 million in 2026, $636.5 million in 2027, and $999.6 million in 2028.

Management Comments

• United Hydrogen is a hydrogen solution provider committed to providing customers with decarbonization solutions tailored to their energy decarbonization goals. Driven by the mission of Living in Harmony with Nature, United Hydrogen operates its business in China through its subsidiaries.
• United Hydrogen's management concluded that the current capital market environment, the cost implications, and the company's need for a swift and efficient listing made a de-SPAC merger the optimal route.
• Unlike a traditional IPO, which can be time-consuming and expensive, the de-SPAC route is expected to offer a more streamlined and cost-effective process with greater certainty around valuation and timing.
• Aimei Health believes that a business combination with United Hydrogen will provide Aimei Health shareholders with an opportunity to participate in a company with significant growth potential.
• Pubco intends to keep any future earnings to finance the expansion of its business, and it does not anticipate that any cash dividends will be paid in the foreseeable future.
• United Hydrogen management believes that adopting a higher growth rate in 2024 compared to 2023 is appropriate.
• United Hydrogen management dedicated significant resources and focus to its de-SPAC transaction with Aimei Health during the fiscal year ended December 31, 2024, which temporarily slowed down the pace of business expansion activities, thereby impacting the achievement of the original projections.

Industry Context

The hydrogen energy industry is in a rapid development phase, characterized by continuously emerging and iterating technologies across the entire value chain, including production, storage, transportation, refueling, and utilization. China is a global leader in hydrogen production, with output increasing from 22.5 million tons in 2019 to 36.6 million tons in 2023 (12.9% CAGR), projected to reach 40.6 million tons by 2028. Green hydrogen, produced via electrolysis, is expected to significantly grow its market share. The number of hydrogen refueling stations in China saw a substantial increase from 56 units in 2019 to 405 units in 2023 (64.0% CAGR), with projections for continued rapid expansion. The market for hydrogen fuel cell systems and vehicles (HFCVs and forklifts) is also experiencing high growth, driven by government support and a shift towards market-driven adoption based on total cost of ownership. The competitive landscape is diverse, with state-owned enterprises and international corporations alongside emerging companies, all vying for market share across the hydrogen value chain segments.

Comparison to Industry Standards

• United Hydrogen's projected revenue growth rate for 2024-2026 is expected to surpass that of all three selected comparable public companies (Plug Power Inc., FuelCell Energy, Inc., Bloom Energy Corporation).
• United Hydrogen's expected EBITDA margins for 2024 and 2025 exceed the average expected EBITDA margins of the three selected comparable companies, and are anticipated to be close to the average in 2026.
• The hydrogen industry, including comparable companies like Plug Power, FuelCell Energy, and Bloom Energy, is generally in an early growth stage, characterized by a lack of stable profits in the past three fiscal years. United Hydrogen is also in this early growth stage.
• United Hydrogen's projected compound annual growth rate (CAGR) over the forecast period (approximately 329%) is roughly the average of two peer companies, Hyliion Holdings Corp. and Advent Technology Holdings, Inc., which went public via SPACs and projected high growth post-2021.
• Comparable Companies (as of Dec 31, 2023, for 2026E):
• Plug Power Inc. (PLUG-US): EV/2026E Revenue: 1.2x, EV/2026E EBITDA: 5.1x
• FuelCell Energy, Inc. (FCEL-US): EV/2026E Revenue: 2.3x, EV/2026E EBITDA: 31.8x
• Bloom Energy Corporation (BE-US): EV/2026E Revenue: 1.3x, EV/2026E EBITDA: 11.1x
• Mean: EV/2026E Revenue: 1.6x, EV/2026E EBITDA: 16.0x
• Median: EV/2026E Revenue: 1.3x, EV/2026E EBITDA: 11.1x
• United Hydrogen's smaller size (revenue of $13.1 million in 2023 vs. PLUG $891.3M, FCEL $123.4M, BE $1,333.5M) is noted, but market capitalization is not considered a significant factor influencing valuation within the current industry context.

Management Changes

Corporate Governance

Legal Proceedings

• No material litigation, arbitration, or governmental proceeding currently pending or contemplated against Pubco, United Hydrogen, or any of their respective subsidiaries or their officers/directors as of December 31, 2023.
• No material Action pending or threatened against Aimei Health or its assets.
• No material Action that Aimei Health has pending against any other Person.
• No material Orders binding on Aimei Health.
• No current or former officers, senior management or directors of any Target Company have been charged with, indicted for, arrested for, or convicted of any felony or any crime involving fraud.
• No Action pending or threatened against a Target Company that challenges the validity, enforceability, ownership, or right to use, sell, license or sublicense any material Intellectual Property.
• No Target Company has received any written notice or claim asserting any infringement, misappropriation, violation, dilution or unauthorized use of Intellectual Property of any other Person.
• No Orders restricting rights of a Target Company to use, transfer, license or enforce any material Intellectual Property.
• No Target Company is currently infringing, or has, in the past five years, infringed, misappropriated or violated any Intellectual Property of any other Person in any material respect.
• No Action involving a Target Company with respect to anti-money laundering is pending or threatened.
• No Action involving Purchaser with respect to anti-money laundering is pending or threatened.
• No Action pending or threatened in writing against Pubco, First Merger Sub or Second Merger Sub.
• No judgment or award unsatisfied against Pubco, First Merger Sub or Second Merger Sub.
• No Order in effect and binding on Pubco, First Merger Sub or Second Merger Sub.

Related Party Transactions

• Aimei Health's Sponsor (Aimei Investment Ltd) acquired 1,725,000 Founder Shares for $25,000 (approx. $0.014/share) and 332,000 Private Placement Units for $3,320,000 ($10.00/unit).
• Aimei Health pays its Sponsor $10,000 per month for administrative services; unpaid balance was $180,000 as of June 30, 2025.
• Sponsor and United Hydrogen jointly provided monthly extension fees to Aimei Health's Trust Account, totaling $1,205,400 in outstanding unsecured promissory notes as of June 30, 2025.
• United Hydrogen generated $26,192,610 in revenues from related parties in 2024 and $7,137,680 in 2023, with significant customers including Foshan Feichi, Shanxi Meijin Huasheng, and Jiaxing Eastern China United Hydrogen.
• United Hydrogen made purchases of $7,729,542 from related party suppliers in 2024 and $1,874,846 in 2023, including Foshan Feichi, Beijing Guohong Hydrogen, and Guohong Hydrogen.
• United Hydrogen had accounts receivable of $23,195,274 from related parties as of December 31, 2024, and accounts payable of $9,566,663 to related parties as of the same date.
• United Hydrogen WFOE acquired 100% equity of Zhejiang Qingyuan and Yixun Chuangneng from their shareholders, including payments to Chuanyan Holdings Limited.
• Zhejiang Qingyuan declared dividends of RMB7,000,000 (approx. $985,415.85) on February 29, 2024, to Shanghai RunQing Management Consulting Partnership Enterprise (Limited Partnership) and Shanghai Qicai Technology Partnership Enterprise (Limited Partnership).
• Hydrogen Jiachuang (Jiaxing) New Energy Operation Co., Ltd. declared dividends of RMB1,300,000 (approx. $183,005.80) on February 29, 2024, to Zhejiang Qingyuan.

Stakeholder Impact

• Shareholders (Aimei Health Public): Will experience immediate and material dilution, with ownership potentially dropping to 0.18% in a maximum redemption scenario. Their influence over Pubco's management will be significantly reduced due to the dual-class structure. Redemption rights are available, but exercising them reduces public float and liquidity. Rights will expire worthless if the business combination is not completed.
• Shareholders (United Hydrogen): Will receive $1.5 billion in Pubco shares, with founder Ms. Xia Ma retaining significant control through Class B shares. Expected to benefit from increased access to capital markets and enhanced market visibility.
• Employees: Key personnel of United Hydrogen are expected to remain with Pubco. Pubco intends to adopt an equity incentive plan to attract, motivate, and retain talent. Aimei Health's current directors and officers will resign.
• Customers: United Hydrogen aims to provide decarbonization solutions and expand its offerings, potentially benefiting customers with more efficient and cost-effective hydrogen solutions. However, customer concentration risk is significant.
• Suppliers: United Hydrogen relies heavily on third-party suppliers, creating risks related to quality, supply chain, and costs. Supplier concentration risk is also a concern.
• Creditors: If Aimei Health liquidates, third-party claims could reduce the funds in the Trust Account available for public shareholders. The Sponsor has agreed to be liable for certain claims to ensure Trust Account proceeds are not reduced below $10.10 per share, but its ability to satisfy this is uncertain.

Next Steps

• Aimei Health shareholders to vote on the Business Combination Proposal, Merger Proposal, Share Issuance Proposal, and Adjournment Proposal at the Extraordinary General Meeting on November 6, 2025.
• Pubco will apply for listing its Class A Ordinary Shares on the Nasdaq Capital Market under the symbol UHL, effective at the time of the Business Combination.
• United Hydrogen must complete CSRC filing procedures and receive CSRC approval under the Overseas Listing Trial Measures prior to the consummation of the Business Combination and listing of Pubco Ordinary Shares on Nasdaq.
• Pubco intends to develop an executive compensation program post-Closing.
• Pubco is expected to enter into independent director appointment agreements with each of its Independent Directors.
• United Hydrogen plans to expand its business by participating in the hydrogen supply chain, establishing a "Giga Plant" in Jiaxing, developing new generation hydrogen fuel cell forklifts, strengthening business in key Chinese locations, expanding overseas (Southeast Asia, Middle East), and exploring green hydrogen opportunities.
• United Hydrogen will continue to invest in technology research and development and collaborate with more technology partners.
• Pubco's board of directors will adopt and approve an equity incentive plan providing for 5% of aggregate Pubco Ordinary Shares immediately after the Business Combination.
• Aimei Health, Pubco, and United Hydrogen will use reasonable best efforts to cause Purchaser Units, Purchaser Ordinary Shares, and Purchaser Rights to be delisted from Nasdaq and terminate SEC registration.

Key Dates

Recommendation

The proposed business combination presents a compelling opportunity to invest in a rapidly growing hydrogen energy solutions provider in China, a sector with strong government support and significant market potential. United Hydrogen's impressive revenue and net income growth in 2024, coupled with its comprehensive business model and strategic expansion plans, are positive indicators. However, the transaction carries substantial risks that warrant caution. The severe dilution for Aimei Health's public shareholders, the concentrated voting power in Ms. Xia Ma through the dual-class structure, and the ongoing regulatory uncertainties in China (including the critical CSRC approval and potential HFCA Act delisting risks) introduce considerable downside. Furthermore, United Hydrogen's historical negative operating cash flows and reliance on shareholder capital injections highlight liquidity concerns. While the long-term growth prospects of the hydrogen industry are attractive, the immediate risks and the potential for adverse regulatory outcomes suggest a 'hold' recommendation. Investors should closely monitor the CSRC approval process, Pubco's post-merger financial performance, and any further regulatory developments in China before making a definitive investment decision.

Keywords

Hydrogen energy, SPAC, de-SPAC, Aimei Health, United Hydrogen, Pubco, Nasdaq listing, China, fuel cell, decarbonization, corporate governance, dual-class shares, SEC filing, merger, acquisition, risk factors, financial reporting, PRC regulations, HFCA Act, PCAOB